Laboratory Corporation of America and OmniSeq have launched the OmniSeq Insight genomic and immune profiling test. The tissue-based test integrates next-generation sequencing technology to advance precision oncology, the firms said. OmniSeq Insight is a pan-cancer solid tumor test for genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression. Results are presented in an easy-to-read report that provides recommendations specific to the patient's results based on a proprietary database that includes information and guidelines from the National Comprehensive Cancer Network. The test is available to US clinicians exclusively through Labcorp and in Canada through Dynacare, a Labcorp company.
Labcorp and OmniSeq, a molecular diagnostics subsidiary of Roswell Park Cancer Institute, signed a distribution agreement in 2017 for OmniSeq's immune profiling and pan-cancer NGS tests, and they extended the deal in 2019.
10x Genomics has begun shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed paraffin-embedded) assay.
The assay employs new chemistry that offers researchers the ability to profile the whole transcriptome in sections from archival FFPE tissue blocks. It offers high sensitivity and the same spatial resolution as fresh frozen samples analyzed with Visium.
The assay comes in two versions with four or 16 reactions per kit.
Standard Molecular has introduced ConnectOTR, a cloud-based platform that seeks to ease the administrative burden on community oncology practices by automating the processes of ordering and interpreting molecular diagnostic tests. The software embeds test selection, ordering, results delivery, and interpretation into electronic health records and clinician workflows.
Sysmex Inostics has launched its HPV-SEQ next-generation sequencing test for measuring HPV DNA in the plasma of patients with HPV-related cancers. The test measures HPV 16 and HPV 18, two of the most common high-risk HPV strains. To assess its future utility in guiding treatment de-escalation strategies, HPV-SEQ has been employed to evaluate levels of circulating HPV alongside the radiographic assessment of therapy response in patients.
Sphere Fluidics and ClexBio have launched the biocompatible Cytrix Microfluidic Hydrogel Kit. The kit combines ClexBio's Cytrix Hydrogel with Sphere Fluidics' Pico-Gen double aqueous biochip to generate defined, reproducible, and tailorable hydrogel microstructures for 3D cell culture, organoids, single-cell analysis, and other applications. This allows researchers to study cells over weeks rather than days in defined microenvironments that mimic the natural extracellular matrix.
The Cytrix Hydrogel overcomes the challenges of existing microfluidic hydrogel formation techniques, such as clogging, temperature control issues, or time-critical mixing procedures, the companies said. It offers cytocompatibility and microfluidic-optimized gelation kinetics, providing researchers with a cell-friendly solution to reduce the effect of harmful temperatures, pH changes, and use of UV light required for existing hydrogel formation techniques. Paired with the Sphere Fluidics Pico-Gen double aqueous biochip and microfluidics, the Cytrix Hydrogel enables efficient encapsulation of mammalian cells, bacteria, and other microorganisms in a homogeneous and defined extracellular matrix that supports cell viability.
Foundation Medicine and Natera have launch the research use version of FoundationOne Tracker, Foundation Medicine’s personalized circulating tumor DNA monitoring assay. FoundationOne Tracker combines Foundation Medicine's tissue-based comprehensive genomic profiling platform with Natera's expertise in ctDNA monitoring.
The assay uses optimized algorithms to identify tumor-specific variants and a personalized design to detect ctDNA in plasma, and is meant for use in both advanced- and early-stage research applications. Additionally, the fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies, the companies said.
Swift Biosciences has released its 2S Turbo v2 DNA library kits for metagenomics studies.
The kit includes a specially formulated PCR master mix that boosts a minimal number of PCR cycles, producing high yields with fewer PCR duplicates. The protocol is available in two formats for adapter and indexing flexibility. It enables manual and automated workflows that are compatible with Swift Normalase technology.
Agilent Technologies has launched its SureSelect Human All Exon V8 tool. The firm said the product is a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GenCode. The tool also covers the TERT promoter and hard-to-capture exons. The firm said the new design spans a 35.1 Mb target region of the human genome and delivers excellent enrichment performance for more uniform coverage, as well as efficient and cost-effective exome sequencing.
Agilent offers the new design in three versions: routine exome sequencing (Exome v8); clinical research sequencing (v8 Clinical Plus); and translational research (v8 UTR Plus).
Cytek Biosciences has launched its Cytek Aurora CS system. The firm said that the platform delivers high resolution capabilities at the single-cell level to resolve and sort challenging cell populations regardless of assay complexity or autofluoresence level. Researchers can use the system to isolate live cells or other particles in microtiter plates or tubes for downstream studies.
Bruker has launched two new TimsTOF instruments, the TimsTOF TrueSCP and TimsTOF Pro 2.
TimsTOF True SCP is the result of a collaboration with Evosep and the laboratory of Matthias Mann at Max Planck Institute of Biochemistry. The platform can achieve fivefold higher ion transmission for data-independent dia-PASEF, or parallel reaction monitoring prm-PASEF methods, Bruker said. The dia-PASEF method has demonstrated true, unbiased 4D proteomics from single cells with quantitation of about 1,5000 proteins/cell, in hundreds of isolated single cells ex situ, in combination with the Evosep One LC with Whisper flow technology. As such, the platform provides ultra-high sensitivity for unbiased single-cell proteomics after laser microdissection of cells, as well as ultra-sensitive neoantigen discovery in immuno-oncology research.
The TimsTOF Pro 2 is designed for robust, unbiased, deep, and quantitative 4D proteomics and 4D epiproteomics for plasma and tissue samples, and from cell culture, Bruker said. New design advances combined with enhanced data-PASEF, dia-PASEF, and prm-PASEF methods enable the detection of more than 6,000 proteins and more than 60,000 peptides by dda-PASEF with 60-minute gradients on 200 ng of digest, the company said. It also has new high-sensitivity methods that enable very good proteome coverage with 10-fold less digest, down to 20 ng, for more than 3,500 protein groups and more than 25,000 unique peptides using a 30-minute gradient. The dia-PASEF workflows on TimsTOF Pro 2 include an improved interface for designing experiments, and can now identify about 8,000 protein groups and 70,000 peptides in 60 minutes on 200 ng of digests, the company said.